CNMDNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
CONMED Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$46.05−0.67 (-1.43%)
Close on Oct 19, 2026
- Market cap
- $1.39B
- P/E (TTM)
- 24.9
- Dividend yield
- 1.30%
CONMED Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General Surgery | $800.13M | $763.03M | $711.59M | $583.94M | $572.21M | $487.75M | $491.78M | $412.91M | $367.45M | $341.42M | 58.2% | +4.9% |
| Orthopedic Surgery | $574.60M | $543.99M | $533.16M | $461.53M | $438.42M | $374.71M | $463.32M | $446.73M | $428.94M | $422.10M | 41.8% | +5.6% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $774.59M | $748.22M | $700.16M | $578.95M | $552.53M | $482.06M | $516.67M | $448.65M | $411.04M | $399.11M | 56.3% | +3.5% |
| Europe, Middle East & Africa | $264.65M | $243.06M | $226.25M | $197.94M | $189.70M | $161.08M | $182.55M | $166.56M | $155.85M | $147.99M | 19.3% | +8.9% |
| Asia Pacific | $208.72M | $194.68M | $197.40M | $162.48M | $171.22M | $140.60M | $160.61M | $146.90M | $138.33M | $128.90M | 15.2% | +7.2% |
| Americas (excluding the United States) | $126.76M | $121.04M | $120.93M | $106.11M | $97.19M | $78.71M | $95.27M | $97.53M | $91.17M | $87.53M | 9.2% | +4.7% |
From the segment and revenue-disaggregation notes of Conmed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.